Decision Resources Group Release: Biosimilar Versions of TNF-alpha Inhibitors and Pegylated IFN-alpha Agents Will Save Healthcare Systems $5.3 Billion in 2020

BURLINGTON, Mass.--(BUSINESS WIRE)--Decision Resources, one of the world’s leading research and advisory firms for pharmaceutical and healthcare issues, finds that biosimilar versions of tumor necrosis factor (TNF)-alpha inhibitors and pegylated interferon (IFN)-alpha agents will save healthcare systems in the United States and EU5 (France, Germany, Italy, Spain and the United Kingdom) $5.3 billion in 2020. According to Biosimilars Advisory Service: Physician Perspectives on Pegylated Interferon-alpha and TNF-alpha Inhibitors in Immune and Infectious Disease, biosimilar TNF-alpha inhibitors will contribute the majority of cost savings.